Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 2:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 669 matching trials from the live ClinicalTrials.gov search.
Not listed No phase listed Observational Accepts healthy volunteers

Ultrasonic Evaluation of Ocular Tissues

NCT00279695
Conditions
Glaucoma, Tumors, Age-Related Macular Degeneration
Interventions
high frequency ultrasound examination
Procedure
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 90 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1996 – 2010
U.S. locations
1
States / cities
New York, New York
Conditions
Age Related Maculopathy, Retinal Degeneration
Interventions
Eccentric Viewing Training for Reading
Procedure
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Age-Related Macular Degeneration
Interventions
AG-013,958
Drug
Lead sponsor
Pfizer
Industry
Eligibility
55 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
30
States / cities
Mesa, Arizona • Oro Valley, Arizona • Phoenix, Arizona + 27 more
Conditions
Age-Related Macular Degeneration, Dry Age-related Macular Degeneration, Nonexudative Age-related Macular Degeneration
Interventions
i-Lumen(TM) AMD, i-Lumen(TM) AMD Sham
Device
Lead sponsor
i-Lumen Scientific, Inc.
Industry
Eligibility
50 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
10
States / cities
Phoenix, Arizona • Walnut Creek, California • Lemont, Illinois + 7 more
Completed Not applicable Interventional Accepts healthy volunteers Results available

BCI and Evaluation of Visual and Task Performance in Subjects With Eye Diseases

NCT03318549
Conditions
Glaucoma, Macular Degeneration, Glaucoma Suspect, Optic Neuropathy, Retinal Degeneration, Visual Pathway Disorder
Interventions
Visual Performance tests, Brain-computer interface
Diagnostic Test · Device
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 90 Years
Enrollment
115 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Miami, Florida
Conditions
Dry Age-related Macular Degeneration, Geographic Atrophy
Interventions
ACU-4429, Matching placebo
Drug
Lead sponsor
Kubota Vision Inc.
Industry
Eligibility
Not listed
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
12
States / cities
Phoenix, Arizona • Beverly Hills, California • Daytona Beach, Florida + 9 more
Conditions
"Wet" Age-Related Macular Degeneration
Interventions
Squalamine Lactate
Drug
Lead sponsor
Genaera Corporation
Industry
Eligibility
50 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
29
States / cities
Beverly Hills, California • Louisville, Colorado • Boynton Beach, Florida + 24 more
Conditions
Macular Degeneration
Interventions
VEGF Trap
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
8
States / cities
Tuscon, Arizona • Loma Linda, California • Chicago, Illinois + 5 more
Conditions
Age-related Macular Degeneration
Interventions
Ranibizumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
50 Years and older
Enrollment
1,097 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
99
States / cities
Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 91 more
Conditions
Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization, Wet Macular Degeneration
Interventions
Tiespectus, Aflibercept
Drug
Lead sponsor
EyeBiotech Ltd.
Industry
Eligibility
50 Years and older
Enrollment
960 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
67
States / cities
Scottsdale, Arizona • Fayetteville, Arkansas • Springdale, Arkansas + 59 more
Conditions
Macular Degeneration
Interventions
abicipar pegol, ranibizumab, sham procedure
Drug · Other
Lead sponsor
Allergan
Industry
Eligibility
50 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Phoenix, Arizona
Conditions
Neovascular Age-related Macular Degeneration
Interventions
CLS-AX, Aflibercept
Drug
Lead sponsor
Clearside Biomedical, Inc.
Industry
Eligibility
50 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
32
States / cities
Phoenix, Arizona • Bakersfield, California • Fullerton, California + 28 more
Conditions
Wet Age-Related Macular Degeneration
Interventions
PTK787, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
65 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
7
States / cities
Beverly Hills, California • Denver, Colorado • Tampa, Florida + 4 more
Conditions
Retinal Drusen, Age-related Macular Degeneration, Macular Degeneration
Interventions
Lumega-Z, AREDS2
Dietary Supplement
Lead sponsor
Guardion Health Sciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Austin, Texas
Conditions
Neovascular Age Related Macular Degeneration
Interventions
OCT, Multifocal ERG, Microperimetry, Ranibizumab Ophthalmic
Device · Drug
Lead sponsor
Retina Macula Institute
Other
Eligibility
50 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Torrance, California
Conditions
Age-Related Macular Degeneration
Interventions
Minocycline
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
55 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Macular Degeneration
Interventions
rhuFab V2 (ranibizumab)
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
50 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Denver, Colorado
Conditions
Choroidal Neovascularization, Macular Degeneration
Interventions
Corticosteroid
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Effects of Sildenafil on Choroidal Thickness in AMD

NCT01830790
Conditions
Age-related Macular Degeneration
Interventions
Sildenafil citrate
Drug
Lead sponsor
Duke University
Other
Eligibility
65 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Neovascular Age-related Macular Degeneration
Interventions
LUBT010 (proposed ranibizumab biosimilar), Lucentis (ranibizumab)
Drug
Lead sponsor
Lupin Ltd.
Industry
Eligibility
50 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
6
States / cities
Beverly Hills, California • Delray Beach, Florida • Hagerstown, Maryland + 3 more
Conditions
Geographic Atrophy of the Macula, Macular Degeneration
Interventions
AVD-104, Avacincaptad
Drug
Lead sponsor
Aviceda Therapeutics, Inc.
Industry
Eligibility
55 Years to 90 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
56
States / cities
Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 50 more
Terminated No phase listed Observational Accepts healthy volunteers

PIIR Study: Comparison of Genetic Tests for Age-Related Macular Degeneration

NCT02779686
Conditions
Age-Related Macular Degeneration (ARMD)
Interventions
Not listed
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
60 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
3
States / cities
Chicago, Illinois • Chesterfield, Missouri • Columbia, Missouri
Conditions
Geographic Atrophy From Age-related Macular Degeneration
Interventions
Not listed
Lead sponsor
University of Utah
Other
Eligibility
65 Years to 90 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Neovascular Age Related Macular Degeneration
Interventions
Lucentis (Treat and extend), Lucentis every 4 weeks, Lucentis every 12 weeks
Drug
Lead sponsor
Retinal Consultants of Arizona
Other
Eligibility
50 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
4
States / cities
Gilbert, Arizona • Mesa, Arizona • Peoria, Arizona + 1 more